Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharmaceuticals on Monday, setting a price target of $74, which is approximately 42.98% below the present share price of $129.79.
Marai expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.62 for the second quarter of 2020.
The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $156.93.
The analysts price targets range from a high of $202 to a low of $74.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $99.48 million and a net profit of -$210.16 million. The company's market cap is $14.89 billion.
According to TipRanks.com, Nomura analyst Christopher Marai is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 48.76% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.